Abstract
This Viewpoint discusses 3 bills introduced recently in Congress that focus on patent eligibility, fraud, and quality and that have major implications for clinical medicine and pharmaceutical development.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have